U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT07470983) titled 'A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism' on March 10.

Brief Summary: This study is a multicenter, randomized, double-blind, placebo-parallel-controlled phase II clinical trial to evaluate the efficacy and safety of HRS-1780 compared with placebo in participants with primary aldosteronism. The study plans to enroll 60 participants.

Study Start Date: March, 2026

Study Type: INTERVENTIONAL

Condition: Primary Aldosteronism

Intervention: DRUG: HRS-1780 Tablets

HRS-1780 Tablets

DRUG: Placebo

Placebo

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Shandong Sunc...